Fluoroquinolones for respiratory infection: Too valuable to overuse (and too valuable to misuse!) [3] (multiple letters)

Chest

Volumn 122, Issue 3, 2002, Pages 1102-1103

  Weiss, Karl ^a   Tillotson, Glenn S ^b   Guthrie, Robert ^c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Public Health Research Laboratory   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG MECHANISM; DRUG USE; HONG KONG; HUMAN; IN VITRO STUDY; LETTER; LOWER RESPIRATORY TRACT INFECTION; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; UNITED STATES;

EID: 0036382838     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.3.1102     Document Type: Letter

References (15)

1. R Guthrie Community-acquired lower respiratory tract infections: etiology and treatment Chest 120 2001 2021 2034
2. JH Williams Jr Fluoroquinolones for respiratory infections: too valuable to overuse Chest 120 2001 1771 1775
3. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention Am J Respir Crit Care Med 163 2001 1730 1754
4. PL Ho RW Yung DN Tsang Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J Antimicrob Chemother 48 2001 659 665
5. R Davidson R Cavalcanti JL Brunton Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance N Engl J Med 346 2002 747 750
6. PE Empey HR Jennings AC Thornton Levofloxacin: failure in a patient with pneumococcal pneumonia Ann Pharmacother 35 2001 687 690
7. C Urban N Rahman X Zhao Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy J Infect Dis 184 2001 794 798
8. K Weiss C Restieri R Gauthier A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae Clin Infect Dis 33 2001 517 522
9. GV Doern GS Tillotson AA Karcic Fluoroquinolone pharmacodynamics and efficacy Chest 120 2001 319 320
10. Weiss K, Restieri C, Dolce P, et al. Increasing resistance of Streptococcus pneumoniae to ciprofloxacin in the province of Quebec, Canada. Paper presented at: 41st ICAAC meeting, American Society for Microbiology, Chicago, IL, December 15–18, 2001, Abstract 707
11. JD Heffelfinger SF Dowell JH Jorgensen Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group Arch Intern Med 160 2000 1399 1408
12. GV Doern Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States Clin Infect Dis 33 suppl 2001 S187 S192
13. RF Grossman J Mukherjee D Vaughan A 1-year community-based health-economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group Chest 113 1998 131 141
14. CJ Destache N Dewan WJ O’Donohue Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis J Antimicrob Chemother 43 suppl 1999 107 113
15. G Tillotson X Zhao K Drlica Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes Lancet Infect Dis 1 2001 145 146